Animal models of FSGS: Lessons for pathogenesis and treatment

Seminars in Nephrology

Volumn 23, Issue 2, 2003, Pages 161-171

  Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; DOXORUBICIN; PUROMYCIN AMINONUCLEOSIDE;

CELL DAMAGE; CYTOTOXICITY; DRUG INDUCED DISEASE; FOCAL GLOMERULOSCLEROSIS; GENE TECHNOLOGY; GENETIC MODEL; GENETIC SUSCEPTIBILITY; KIDNEY DISEASE; KNOCKOUT GENE; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION;

EID: 0037350930     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2003.50015     Document Type: Review

References (87)

1. Schwartz MM, Korbet SM: Primary focal segmental glomerulosclerosis: Pathology, histological variants, and pathogenesis. Am J Kidney Dis 22:874-883, 1993
2. D'Agati V: The many masks of focal segmental glomerulosclerosis. Kidney Int 46:1223-1241, 1994
3. Howie AJ, Kizaki T, Beaman M, et al: Different types of segmental sclerosing glomerular lesions in six experimental models of proteinuria. J Pathol 157:141-151, 1989
4. Oikawa T, Freeman M, Lo W, et al: Modulation of plasminogen activator inhibitor-1 (PAI-1) in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51:164-172, 1997
5. Chanutin A, Ferris EB: Experimental renal insufficiency produced by partial nephrectomy. Arch Intern Med 49:767-787, 1932
6. Hostetter TH, Olson JL, Rennke HG, et al: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241:F85-F93, 1981
7. Morrison AB, Howard RM: The functional capacity of hypertrophied nephrons: Effect of partial nephrectomy on the clearance of inulin and PAH in the rat. J Exp Med 123:829-844, 1966
8. Shimamura T, Morrison AB: A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 79:95-106, 1975
9. Rich AR: A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. Bull Johns Hopkins Hosp 100:173-175, 1957
10. Yoshida Y, Fogo A, Shiraga H, et al: Serial micropuncture analysis of single nephron function in the rat model of subtotal renal ablation. Kidney Int 33:855-867, 1988
11. Gretz N, Waldherr R, Strauch M: The remnant kidney model, in Gretz N, Strauch M (eds): Experimental and Genetic Rat Models of Chronic Renal Failure. Karger, Basel, 1993, pp 1-28
12. Correa-Rotter R, Hostetter TH, Manivel JC, et al: Renin expression in renal ablation. Hypertension 20:483-490, 1992
13. Nyengaard JR: Number and dimensions of rat glomerular capillaries in normal development and after nephrectomy. Kidney Int 43:1049-1057, 1993
14. Lax DS, Benstein JA, Tolbert E, et al: Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. Kidney Int 41:1527-1534, 1992
15. Lee GS, Nast CC, Peng SC, et al: Differential response of glomerular epithelial and mesangial cells after subtotal nephrectomy. Kidney Int 53:1389-1398, 1998
16. Kujubu DA, Norman JT, Herschman HR, et al: Primary response gene expression in renal hypertrophy and hyperplasia: Evidence for different growth initiation processes. Am J Physiol 260:F823-F827, 1991
17. Aschinberg LC, Koskimies O, Bernstein J. et al: The influence of age on the response to renal parenchymal loss. Yale J Biol Med 51:341-345, 1978
18. O'Donnell MP, Kasiske BL, Raij L, et al: Age is a determinant of the glomerular morphologic and functional responses to chronic nephron loss. J Lab Clin Med 106:308-313, 1985
19. Ikoma M, Yoshioka T, Ichikawa I, et al: Mechanism of the uniqae susceptibility of deep cortical glomeruli of maturing kidneys to severe focal glomerular sclerosis. Pediatr Res 28: 270-276, 1990
20. Schena FP, Strippoli GF, Wankelmuth P: Renal growth factors: Past, present and future. Am J Nephrol 19:308-312, 1999
21. Zidek V, Musilova A, Vorlieek J, et al: Quantitative trait loci for compensatory renal hypertrophy in the mouse. Biochem Biophys Res Commun 248:473-475, 1998
22. Combs HL, Shankland SJ, Setzer SV, et al: Expression of the cyclin kinase inhibitor, p27kip1, in developing and mature human kidney. Kidney Int 53:892-896, 1998
23. Shankland SJ: Cell cycle regulatory proteins in glomerular disease. Kidney Int 56:1208-1215, 1999
24. Megyesi J, Price PM, Tamayo E, et al: The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci U S A 96:10830-10835, 1999
25. Fries JWU, Sandstrom DJ, Meyer TW, et al: Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab Invest 60:205-218, 1989
26. Kriz W, Hosser H, Hahnel B, et al: From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: A histopathological study in rat models and human glomerulopathies. Nephrol Dial Transplant 13:2781-2798, 1998
27. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
28. Nath KA, Kren SM, Hostetter TH: Dietary protein restriction in established renal injury in the rat. Selective role of glomerular capillary pressure in progressive glomerular dysfunction. J Clin Invest 78: 1199-1205, 1986
29. Fogo A, Ichikawa I: Glomerular growth promoter - the common channel to glomerular sclerosis, in Stein JH, Mitch WE (eds): Contemporary Issues in Nephrology: The Progressive Nature of Renal Disease (ed 2). New York, Churchill Livingstone, 1992, pp 23-54
30. Neuringer JR, Anderson S, Brenner BM: The role of systemic and intraglomerular hypertension, in Stein JH, Mitch WE (eds): Contemporary Issues in Nephrology - The Progressive Nature of Renal Disease (ed 2). New York, Churchill Livingstone, 1992, pp 1-21
31. Harris RC, Haralson MA, Badr KF: Continuous stretch-relaxation in culture alters mesangial cell morphology, growth characteristics, and metabolic activity. Lab Invest 66:548-554, 1992
32. Hostetter TH, Meyer TW, Rennke HG, et al: Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int 30:509-517, 1986
33. Anderson S, Meyer TW, Rennke HG, et al: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612-619, 1985
34. Yoshida Y, Fogo A, Ichikawa I: Effects of anti-hypertensive drugs on glomerular morphology: A close linkage between their anti-hypertrophic and anti-sclerotic action on remnant glomeruli. Kidney Int 36:626-635, 1989
35. Fogo AB: Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int 57: S15-S21, 2000 (suppl 75)
36. Fogo A: Progression and potential regression of glomerulosclerosis. Nephrology Forum. Kidney Int 59:804-819, 2001
37. Fogo AB: Mesangial matrix modulation and glomerulosclerosis. Exp Nephrol 7:147-159, 1999
38. Fogo AB: The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 35:179-188, 2000
39. Oda H. Keane WF: Recent advances in statins and the kidney. Kidney Int Suppl 71:S2-S5, 1999
40. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am J Pathol 122:481-487, 1986
41. Anderson S, Diamond JR, Karnovsky MJ, et al: Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 82:1757-1768, 1988
42. Glasser RJ, Velosa JA, Michael AF: Experimental model of focal sclerosis. I, Relationship to protein excretion in aminonucleoside nephrosis. Lab Invest 36:519-526, 1977
43. Fogo A. Yoshida Y, Glick AD, et al: Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 82:322-330, 1988
44. Okuda S, Oh Y, Tsuruda H, et al: Adriamycin-induced nephropathy as a model of chronic progressive glomerular damage. Kidney Int 29:502-510, 1986
45. Bertani T, Rocchi G, Sacchi G, et al: Adriamycin-induced glomerulosclerosis in the rat. Am J Kidney Dis 7:12-19, 1986
46. Chen A, Sheu L-F, Ho Y-S, et al: Experimental focal segmental glomerulosclerosis in mice. Nephron 78:440-452, 1998
47. Wang Y, Wang YP, Tay YC, et al: Progressive adriamycin nephropathy in mice: Sequence of histologic and immunohistochemical events. Kidney Int 58:1797-1804, 2000
48. Chen A, Wei C-H, Sheu L-F, et al: Induction of proteinuria by adriamycin or bovine serum albumin in the mouse. Nephron 69:293-300, 1995
49. Fishman JA, Karnovsky MJ: Effects of the aminonucleoside of puromycin on glomerular epithelial cells in vitro. Am J Pathol 118:398-407, 1985
50. Diamond JR, Bonventre JV, Karnovsky MJ: A role for oxygen free radicals in aminonucleoside nephrosis. Kidney Int 29:478-483, 1986
51. Kawaguchi M, Yamada M, Wada H, et al: Roles of oxygen species in glomerular epithelial cell injury in vitro caused by puromycin aminonucleoside. Toxicology 72:329-340, 1992
52. Yoshioka T, Ichikawa I, Fogo A: Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality. J Am Soc Nephrol 2:902-912, 1991
53. Milner LS, Wei SH, Houser MT: Amelioration of glomerular injury in doxorubicin hydrochloride nephrosis by dimethylthiourea. J Lab Clin Med 118:427-434, 1991
54. Kojima K, Matsui K, Nagase M: Protection of alpha(3) integrin-mediated podocyte shape by superoxide dismutase in the puromycin aminonucleoside nephrosis rat. Am J Kidney Dis 35:175-1185, 2000
55. Kemeny E, Mihatsch MJ, Durmuller U, et al: Podocytes lose their adhesive phenotype in focal segmental glomerulosclerosis. Clin Nephrol 43:71-83, 1995
56. Trachtman H, Del Pizzo R, Futterweit S, et al: Taurine attenuates renal disease in chronic puromycin aminonucleoside nephropathy. Am J Physiol 262: F117-F123, 1992
57. Ahola H, Wang SX, Luimula P. et al: Cloning and expression of the rat nephrin homolog. Am J Pathol 155:907-913, 1999
58. Breiteneder-Geleff S, Matsui K, Soleiman A, et al: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 151:1141-1152, 1997
59. Shiiki H, Sasaki Y, Nishino T, et al: Cell proliferation and apoptosis of the glomerular epithelial cells in rats with puromycin aminonucleoside nephrosis. Pathobiology 66:221-229, 1998
60. Kim YH, Goyal M, Kurnit D, et al: Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 60:957-968, 2001
61. Cahill MM, Ryan GB, Bertram JF: Biphasic glomerular hypertrophy in rats administered puromycin aminonucleoside. Kidney Int 50:768-775, 1996
62. Fan L, Wakayama T, Yokoyama S, et al: Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis. Nephron 90:95-102, 2002
63. Baboolal K, Meyer TW: Tubulointerstitial injury and impaired renal function after recovery from acute puromycin nephrosis. Am J Physiol 269:F331-F338, 1995
64. Olson JS, Rennke HG, Venkatachalam MA: Alteration in the charge and size selectivity barrier of the glomerular filter in aminonucleoside nephrosis in rats. Lab Invest 44:271-279. 1981
65. Hjalmarsson C, Ohlson M, Haraldsson B: Puromycin aminonucleoside damages the glomerular size barrier with minimal effects on charge density. Am J Physiol 281:F503-F512, 2001
66. Levidiotis V, Kanellis J, Ierino FL, et al: Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int 60:1287-1296, 2001
67. Okuda S, Oochi N, Wakisaka M, et al: Albuminuria is not an aggravating factor in experimental focal glomerulosclerosis and hyalinosis. J Lab Clin Med 119:245-253, 1992
68. Yoshioka T, Shiraga H, Yoshida Y, et al: "Intact nephrons" as the primary origin of proteinuria in chronic renal disease: A study in the rat model of subtotal nephrectomy. J Clin Invest 82:1614-1623, 1988
69. Tanaka R, Kon V, Yoshioka T. et al: Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 45:537-543, 1994
70. Ou ZL, Natori Y, Natori Y: Transient and sequential expression of chemokine mRNA in glomeruli in puromycin aminonucleoside nephrosis. Nephron 85:254-257, 2000
71. Magil AB, Pichler RH, Johnson RJ: Osteopontin in chronic puromycin aminonucleoside nephrosis. J Am Soc Nephrol 8:1383-1390, 1997
72. Wang Y, Wang YP, Tay YC, et al: Role of CD8(+) cells in the progression of murine adriamycin nephropathy. Kidney Int 59:941-949, 2001
73. Huang S, Schaefer RM, Reisch S, et al: Suppressed activities of cathepsins and metalloproteinases in the chronic model of puromycin aminonucleoside nephrosis. Kidney Blood Press Res 22:121-127, 1999
74. Ebihara I, Nakamura T, Tomino Y, et al: Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis. Nephrol Dial Transplant 12:1001-1006, 1997
75. Marinides GN, Groggel GC, Cohen AH, et al: Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. Kidney Int 37:749-757, 1990
76. El Nahas AM, Bassett AH, Cope GH, et al: Role of growth hormone in the development of experimental renal scarring. Kidney Int 40:29-34, 1991
77. Kren S, Hostetter TH: The course of the remnant kidney model in mice. Kidney Int 56:333-337, 1999
78. Esposito C, He CJ, Striker GE, et al: Nature and severity of the glomerular response to nephron reduction is strain-dependent in mice. Am J Pathol 154:891-897, 1999
79. Wang Q, Hummler E, Nussberger J, et al: Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: Role of renin genes. J Am Soc Nephrol 13:1509-1516, 2002
80. Grond J, Muller EW, van Goor H, et al: Differences in puromycin aminonucleoside nephrosis in two rat strains. Kidney Int 33:524-529, 1988
81. Miner JH, Morello R, Andrews KL, et al: Transcriptional induction of slit diaphragm genes by Lmxlb is required in podocyte differentiation. J Clin Invest 109:1065-1072, 2002
82. Shih NY, Li J, Karpitskii V, et al: Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 286:312-315, 1999
83. Shih NY, Li J, Cotran R, et al: CD2AP localizes to the slit diaphragm and binds to nephrin via a novel C-terminal domain. Am J Pathol 159:2303-2308, 2001
84. Kaplan JM, Kim SH, North KN, et al: Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251-256, 2000
85. Takeda T, McQuistan T, Orlando RA, et al: Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest 108:289-301, 2001
86. Le Berre L, Godfrin Y, Günther E, et al: Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats. J Clin Invest 109:491-498, 2002
87. Antignac C: Genetic models: Clues for understanding the pathogenesis of idiopathic nephrotic syndrome. J Clin Invest 109:447-449, 2002